Xin Lang Cai Jing·2025-10-17 04:30Core Insights - Johnson & Johnson is in talks to acquire its immunotherapy partner Protagonist Therapeutics for over 28.5 billion RMB (approximately 4 billion USD) [1] - The key asset in this acquisition is the oral cyclic peptide IL-23 inhibitor icotrokinra, which is expected to change the treatment landscape for psoriasis [1] Group 1: Acquisition Details - The two companies are currently collaborating on the development of icotrokinra for treating plaque psoriasis and ulcerative colitis [2] - Johnson & Johnson holds exclusive commercialization rights for icotrokinra [2] - The acquisition would help Johnson & Johnson strengthen its product line as its blockbuster immunotherapy drug Stelara recently lost patent exclusivity in the U.S. [2] Group 2: Drug Development Progress - Icotrokinra has shown success in two Phase 3 trials for plaque psoriasis [4] - Johnson & Johnson's CEO stated that if approved, icotrokinra would have a significant market impact [4] - The companies are also looking to expand icotrokinra's application to other immune and inflammatory diseases, with successful results reported in a Phase 2b trial for ulcerative colitis [4] Group 3: Drug Mechanism - Icotrokinra is a targeted oral peptide that selectively blocks the IL-23 receptor (IL-23R), which plays a critical role in the activation of pathogenic T cells in moderate to severe plaque psoriasis [6] - The drug binds with high affinity to IL-23R and exerts strong selective inhibition of IL-23 signaling in human T cells [6] Group 4: Company Background - Johnson & Johnson, founded in 1886, is one of the most comprehensive and widely distributed healthcare product companies globally, with operations in medical technology and innovative pharmaceuticals [7] - In 2023, Johnson & Johnson successfully completed the spin-off of its consumer health business and announced a brand refresh, consolidating its medical technology and innovative pharmaceuticals under the Johnson & Johnson name [7]